Dec 20, 2024 · Waldenstrom macroglobulinemia (mak-roe-glob-u-lih-NEE-me-uh) is a type of cancer that begins in the white blood cells. Waldenstrom macroglobulinemia is considered a type of non-Hodgkin's lymphoma. It's sometimes called lymphoplasmacytic lymphoma.

Dec 5, 2019 · Waldenström macroglobulinemia (WM) is an uncommon lymphoma (∼1%-2% of hematological malignancies) with unique features, characterized by the accumulation of lymphoplasmacytic cells that produce monoclonal immunoglobulin M (IgM).

LPL with IgM detectable on blood tests is called Waldenström’s macroglobulinaemia (WM). It is named after the scientist who first described it. Around 1 in 20 cases of LPL produce a different antibody (usually IgG), or don’t produce abnormal levels of antibodies at all.

4 days ago · Waldenström macroglobulinemia (WM) — also known as lymphoplasmacytic lymphoma — is a rare, slow-growing cancer that affects your blood cells. WM happens when genetic mutations change your B cells. Healthcare providers can’t cure this condition, but they do have treatments that can manage symptoms.

Dec 11, 2023 · The most common type of LPL is Waldenstrom macroglobulinemia (WM), which is characterized by abnormal production of immunoglobulin (antibodies). WM is sometimes mistakenly referred to as...

This review summarizes the clinical, laboratory, and histologic features of LPL/WM, with particular emphasis on unique aspects of LPL/WM that may aid in accurate diagnosis.

WM is the most common form of a sub-type of non-Hodgkin lymphoma called lymphoplasmacytic lymphoma (LPL). WM cells are lymphoplasmacytic, meaning they have features of both plasma cells and lymphocyte cells.

Jan 24, 2024 · The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newl …

Nov 5, 2024 · An IgM monoclonal gammopathy and bone marrow involvement defines Waldenstrom Macroglobulinemia (WM), and non-IgM LPL is rare. Treatments for LPL/WM have evolved over the past decade with the availability of targeted therapies, especially Bruton's kinase inhibitors (BTKi).

Waldenström macroglobulinemia (WM) is an indolent (slow-growing) subtype of non-Hodgkin lymphoma that afects small lymphocytes (white blood cells). WM is rare, with an incidence rate of about 6 cases per million people per year in the United States.